Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus Clinical Trial

Official title:

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03436498
• Other study ID #: PDY15083
• Secondary ID: U1111-1200-1241
• Status: Completed
• Phase: Phase 1
• Start date: May 10, 2018
• Est. completion date: October 6, 2018

Study information

• Verified date: April 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

• To assess the safety of SAR341402 and NovoLog® when used in external insulin pumps in terms of the number of patients with infusion set occlusions.

Secondary Objectives:

• To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of unexplained hyperglycemia.

• To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of:

• Intervals for infusion set changes.

• Number of patients with insulin pump for "non-delivery" alarm.

• Patient observation of infusion set occlusion.

• Adverse events and serious adverse events.

• Number of patients with hypoglycemic events [according to ADA (American Diabetes Association) Workgroup on hypoglycemia].

Description:

The study duration for each patient will be approximately 10 weeks, including a 2-week screening period, 2 treatment periods of 4 weeks each, and 1-day post-treatment safety follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: October 6, 2018
• Est. primary completion date: October 6, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Male and female patients with Type 1 diabetes mellitus (T1DM).

• Age greater than or equal to 18 at the screening visit.

• Diabetes diagnosed at least 12 months before screening visit.

• At least 1 year of insulin treatment with at least 6 months of CSII (Continuous Subcutaneous Insulin Infusion) treatment with an external insulin pump.

• Demonstration of successful use of insulin pump and performing of a minimum of 4 blood glucose checks per day during screening.

• Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for T1DM patients.

• Signed written informed consent.

Exclusion criteria:

• Hemoglobin A1c (HbA1c) =8.5% at screening.

• Diabetes other than T1DM.

• History of infection at the infusion site within 3 months prior to the screening visit (Visit 1).

• Use of oral glucose-lowering agents or any injectable glucose-lowering agents other than insulin during the 3 months before screening visit.

• Hospitalization for recurrent diabetic ketoacidosis (DKA) in the last 6 months before screening visit.

• History of severe hypoglycemia requiring emergency room admission or hospitalization in the last 6 months before screening visit.

• Hypoglycemic unawareness as judged by the Investigator in the last 6 months before the screening visit.

• Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study.

• Known history of illegal drug or alcohol abuse within 6 months prior to the time of screening.

• Use of investigational drug(s) within 3 months or 5 half-lives, whichever is longer, prior to the screening visit.

• Patients who had previously received SAR341402 in any other clinical trial.

• Any contraindication to the use of NovoLog® as defined in the national product labels; history of hypersensitivity to NovoLog® or to any of the excipients.

• Pregnancy and lactation.

• If female, pregnancy [defined as positive ß-HCG (Human Chorionic Gonadotropin) in blood or in urine], breast-feeding.

• Patient is an employee or relative of an employee of the sponsor.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Insulin aspart SAR341402
Pharmaceutical form: Solution Route of administration: Subcutaneous
• Insulin aspart
Pharmaceutical form: Solution Route of administration: Subcutaneous

Locations

Country	Name	City	State
United States	Investigational Site Number 8400002	Denver	Colorado
United States	Investigational Site Number 8400001	Little Rock	Arkansas
United States	Investigational Site Number 8400003	West Des Moines	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

References & Publications (1)

Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Ty — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Infusion set occlusions	Number of patients with infusion set occlusions. Infusions set occlusions are defined as infusion set change due to failure to correct hyperglycemia (plasma glucose = 250 mg/dL [13.9 mmol/L]) by insulin bolus via the insulin pump.	At week 4 from baseline of each treatment
Secondary	Unexplained hyperglycemia	Number of patients with unexplained hyperglycemia. Unexplained hyperglycemia is defined as plasma glucose equal or above 250 mg/dL (13.9 mmol/L) whether or not corrected by a bolus through the insulin pump with no apparent material defects, medical, dietary, insulin dosing or pump failure. This will include infusion set occlusion as defined in the primary endpoint.	At week 4 from baseline of each treatment
Secondary	Intervals for infusion set changes	Intervals for infusion set changes will be derived as number of days in the treatment period divided by the number of infusion set changes in the treatment period.	At week 4 from baseline of each treatment
Secondary	Number of patients with insulin pump alarms for "non-delivery"	Number of patients with insulin pump "non-delivery" alarms (independent of confirmation of occlusion by hyperglycemia and failure to correct hyperglycemia by insulin bolus via the insulin pump).	At week 4 from baseline of each treatment
Secondary	Patient observation of infusion set occlusion	Patient observation of infusion set occlusion (independent of confirmation of occlusion by hyperglycemia and failure to correct hyperglycemia by insulin bolus via the insulin pump).	Up to 10 weeks
Secondary	Adverse events and serious adverse events	Number patients with adverse events and/or serious adverse events, including bruising at the infusion site and injection site, and hypersensitivity reactions.	Up to 10 weeks
Secondary	Number of patients with hypoglycemic events	Number of patients with hypoglycemic events.	At week 4 from baseline of each treatment